Zoll Medical Corporation (NasdaqGS: ZOLL) announced today that in a
"Best Original Resuscitation Science” presentation at the American Heart
Association’s Resuscitation Science Symposium (ReSS) in Orlando Florida,
Joseph P. Ornato, M.D., and Mary Ann Peberdy, M. D., reported nearly
doubling the resuscitation and survival rates from out-of-hospital
cardiac arrest due to a comprehensive treatment protocol established
between Virginia Commonwealth University Medical Center (VCU) and the
Richmond Ambulance Authority (RAA).
The authors reported an improvement in the return of spontaneous
circulation (ROSC) from 25 percent in 2001 to 46 percent in 2008. In
addition, the survival to hospital discharge rate, with a national
average less than 7 percent, increased from 9.7 percent in 2003 to 17.9
percent at the end of 2008. A second study looking only at hospital
admissions, also presented by Drs. Ornato and Peberdy at ReSS, showed
the survival rate to hospital discharge improving from 19 percent in
2001-2003 to 49 percent in 2008-2009 after implementation of this new
treatment protocol.
Dr. Ornato, Chair of the Department of Emergency Medicine at VCU School
of Medicine and Operational Medical Director of RAA, and Dr. Peberdy,
Professor of Medicine and Emergency Medicine in the Division of
Cardiology at VCU School of Medicine, noted the two goals of the
initiative:
-
To restart the heart as quickly as possible following onset of cardiac
arrest
-
To bring resuscitated patients to a single specialized
post-resuscitation facility.
Both programs utilize advanced technology found in ZOLL products. These
include the ZOLL AutoPulse®, a revolutionary non-invasive
cardiac support pump, the ZOLL Intravascular Temperature Management
(IVTM™) system, and the E Series® Monitor Defibrillators.
-
The AutoPulse was used both in the pre-hospital and hospital settings
to provide consistent, uninterrupted chest compressions resulting in
blood flow during SCA that is simply not possible with human hands.
-
ZOLL's IVTM gives health care providers the power and control they
need to rapidly, safely, and effectively manage the core body
temperature of critically ill or surgical patients. All ZOLL patented
catheter designs combine precise temperature management with the
critical care functions of a standard central venous catheter.
-
The E Series monitor defibrillators include Real CPR Help® real-time
feedback and See-Thru CPR®, industry-unique filtering
technology that allows clinicians to view a patient’s underlying
cardiac rhythm by filtering CPR artifact during resuscitation efforts.
"We’re pleased that our technological innovations have been able to
contribute to the improved survival rates reported by Drs. Ornato and
Peberdy,” said Jonathan A. Rennert, President of ZOLL. "The VCU-RAA
initiative clearly demonstrates the impact an alliance between a
hospital and EMS agency can have in advancing resuscitation care.”
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and
software solutions that help advance emergency care and save lives,
while increasing clinical and operational efficiencies. With products
for defibrillation and monitoring, circulation and CPR feedback, data
management, fluid resuscitation, and therapeutic temperature management,
ZOLL provides a comprehensive set of technologies which help clinicians,
EMS and fire professionals, and lay rescuers treat victims needing
resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company
for the past three years, ZOLL develops and manufactures its products in
the United States, in California, Colorado, Illinois, Massachusetts,
Pennsylvania, and Rhode Island. More than 400 direct sales and service
representatives, 1,100 business partners, and 200 independent
representatives serve our customers in over 140 countries around the
globe. For more information, visit www.zoll.com.
Certain statements contained in this press release, including
statements regarding the future business of the Company, and other
statements contained herein regarding matters that are not historical
facts, are "forward-looking” statements (as defined in the Private
Securities Litigation Reform Act of 1995). Because such statements are
subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements include, but are
not limited to, those factors discussed in the section entitled "Risk
Factors” in the Company's Quarterly Report on Form 10-Q filed with the
SEC on August 7, 2009. You should not place undue reliance on the
forward-looking statements in this press release, and the Company
disavows any obligation to update or supplement those statements in the
event of any changes in the facts, circumstances, or expectations that
underlie those statements.
Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill
Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, CodeNet, E Series,
Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL
Medical Corporation. IVTM is a trademark of ZOLL Medical Corporation.
All product names are the property of their respective owners.
